Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular Carcinoma

Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Hepatocellular Carcinoma

NCT05010434 ·Status: UNKNOWN ·Phase: PHASE2

A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)

NCT01801163 ·Status: WITHDRAWN ·Phase: PHASE1

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

NCT05010681 ·Status: RECRUITING ·Phase: PHASE2

Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma

NCT03881501 ·Status: UNKNOWN

Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma

NCT04042805 ·Status: UNKNOWN ·Phase: PHASE2

Targeted Internal Radiation Therapy in Advanced HCC Patients.

NCT02724267 ·Status: COMPLETED ·Phase: NA

HAIC Combined With Donafenib and Sintilimab for Unresectable ICC

NCT05348811 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC

NCT06904014 ·Status: RECRUITING ·Phase: PHASE2

MB07133 for the Treatment of Patients With Unresectable Hepatocellular Carcinoma

NCT06141096 ·Status: RECRUITING ·Phase: PHASE2

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

NCT05924997 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Donafenib Plus Sintilimab for Advanced HCC

NCT05162352 ·Status: COMPLETED ·Phase: PHASE2

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

NCT04220944 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC

NCT04843943 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative Resection

NCT04682210 ·Status: UNKNOWN ·Phase: PHASE3

A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma

NCT04635527 ·Status: TERMINATED ·Phase: PHASE1

Combination of Sintilimab and Stereotactic Body Radiotherapy in Advanced Metastatic HCC

NCT04547452 ·Status: UNKNOWN ·Phase: PHASE2

SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma

NCT04560894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3

Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma

NCT03908840 ·Status: UNKNOWN ·Phase: PHASE1

The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies

NCT05487443 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular Carcinoma

NCT05621499 ·Status: NOT_YET_RECRUITING ·Phase: NA

Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)

NCT03510871 ·Status: COMPLETED ·Phase: PHASE2

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

NCT03521219 ·Status: UNKNOWN ·Phase: PHASE2

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

NCT03516071 ·Status: COMPLETED ·Phase: PHASE2

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

NCT05519410 ·Status: UNKNOWN ·Phase: PHASE2

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

NCT06397222 ·Status: RECRUITING ·Phase: PHASE2